A polyethylene terephthalate bulked continuous filament is manufactured by steps of melt-spinning, multi-step stretching a polyethylene terephthalate chip and a master batch chip for coloring, passing through a texturing nozzle, cooling, and winding and has an elastic modulus of 1.00E+07 to 5.00E+09Pa at a temperature range of 10° C. to 200° C., the filament being manufactured by steps of melt-spinning a polyethylene terephthalate chip and a master batch chip for coloring, multi-step stretching, passing through a texturing nozzle, cooling, and winding.

A polyethylene terephthalate bulked continuous filament is manufactured by steps of melt-spinning, multi-step stretching a polyethylene terephthalate chip and a master batch chip for coloring, passing through a texturing nozzle, cooling, and winding and has an elastic modulus of 1.00E+07 to 5.00E+09Pa at a temperature range of 10° C. to 200° C., the filament being manufactured by steps of melt-spinning a polyethylene terephthalate chip and a master batch chip for coloring, multi-step stretching, passing through a texturing nozzle, cooling, and winding.

Disclosed are a blood filter which exhibits excellent leukocyte elimination performance as well as significantly improved blood throughput per unit time and erythrocyte recovery rate and a method of manufacturing the same. The blood filter of the present invention includes a pre-treatment filter which is a laminate of first non-woven fabrics having a mean fiber diameter of 5 to 30 μm and a mean pore size of 10 to 30 μm, and a main filter which is a laminate of second non-woven fabrics having a mean fiber diameter of 1 to 5 μm, a mean pore size of 5 to 10 μm and a mean pore size distribution rate of 30% or more. A filling density of the pre-treatment filter and a filling density of the main filter, with respect to a target blood throughput of the blood filter, are 0.1 g/100 ml to 1 g/100 ml and 1 g/100 ml to 3 g/100 ml, respectively.

Disclosed are a blood filter which exhibits excellent leukocyte elimination performance as well as significantly improved blood throughput per unit time and erythrocyte recovery rate and a method of manufacturing the same. The blood filter of the present invention includes a pre-treatment filter which is a laminate of first non-woven fabrics having a mean fiber diameter of 5 to 30 μm and a mean pore size of 10 to 30 μm, and a main filter which is a laminate of second non-woven fabrics having a mean fiber diameter of 1 to 5 μm, a mean pore size of 5 to 10 μm and a mean pore size distribution rate of 30% or more. A filling density of the pre-treatment filter and a filling density of the main filter, with respect to a target blood throughput of the blood filter, are 0.1 g/100 ml to 1 g/100 ml and 1 g/100 ml to 3 g/100 ml, respectively.

Described herein are various three-dimensional fiber structures that have multiple polymer fiber layers with an active therapeutic agent entrained in the polymer fiber layers. Further described are methods for forming the three-dimensional fiber structures where the method includes centrifugal spinning of an emulsion containing polymer(s) and the active therapeutic agent(s).

Articles of wear having one or more textiles that include a low processing temperature polymeric composition and a high processing temperature polymeric composition, and methods of manufacturing the same are disclosed. The low processing temperature polymeric composition and the high processing temperature polymeric composition can be selectively incorporated into a textile to provide one or more structural properties and/or other advantageous properties to the article. The textile can be thermoformed to impart such structural and/or other advantageous properties to the article of wear. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Articles of wear having one or more textiles that include a low processing temperature polymeric composition and a high processing temperature polymeric composition, and methods of manufacturing the same are disclosed. The low processing temperature polymeric composition and the high processing temperature polymeric composition can be selectively incorporated into a textile to provide one or more structural properties and/or other advantageous properties to the article. The textile can be thermoformed to impart such structural and/or other advantageous properties to the article of wear. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

A fiber structure can be used as a cell scaffold material, which fiber structure includes a multifilament formed by bundling monofilaments having an average fiber diameter of 1 to 15 μm, wherein each of the monofilaments satisfies Formula (1): (Y/X)×100>50 . . . (1) wherein, in Formula (1), X represents the number of monofilaments for which the average crossing angle is investigated, and Y represents the number of monofilaments having an average crossing angle of not more than 25° in X.

A fiber structure can be used as a cell scaffold material, which fiber structure includes a multifilament formed by bundling monofilaments having an average fiber diameter of 1 to 15 μm, wherein each of the monofilaments satisfies Formula (1): (Y/X)×100>50 . . . (1) wherein, in Formula (1), X represents the number of monofilaments for which the average crossing angle is investigated, and Y represents the number of monofilaments having an average crossing angle of not more than 25° in X.

Nonwoven fabrics having a plurality of fibers that are bonded to each other to form a coherent web, wherein the fibers comprise a blend of a polylactic acid (PLA) and at least one secondary alkane sulfonate are provided. The nonwoven fabrics exhibit increased tensile strengths, elongation and toughness.